Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
131
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen

Hung-Chin Tsai1 Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan;3 Department of Parasitology, Kaohsiung Medical University, Kaohsiung, Taiwan;4 Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan;5 Shu-Zen Junior College of Medicine and Management, Kaohsiung, TaiwanCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-5441-4386View further author information
ORCID Icon,
I-Tzu Chen1 Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, TaiwanView further author information
,
Hui-Min Chang6 Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;7 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan;8 Department of Pharmacy and Graduate Institute of Pharmaceutical Technology, Tajen University, Pingtung, TaiwanView further author information
,
Susan Shin-Jung Lee1 Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0001-5162-2414View further author information
ORCID Icon &
Yao-Shen Chen1 Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanView further author information
Pages 3857-3869 | Published online: 20 Jul 2022

References

  • Wong A, Goldstein D, Mallolas J, et al. Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) in treatment-naive adults with HIV-1 and transmitted nonnucleoside reverse transcriptase inhibitor resistance mutations. J Acquir Immune Defic Syndr. 2019;82:e47–e49. doi:10.1097/QAI.0000000000002153
  • Molina JM, Squires K, Sax PE, et al; DRIVE-FORWARD Trial Group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, Phase 3 trial. Lancet HIV. 2020;7:e16–e26. doi:10.1016/S2352-3018(19)30336-4
  • Orkin C, Molina JM, Lombaard J, et al. Once-daily doravirine in human immunodeficiency virus type 1-infected, antiretroviral-naive adults: an integrated efficacy analysis. Clin Infect Dis. 2020;70:1344–1352. doi:10.1093/cid/ciz424
  • Johnson M, Kumar P, Molina JM, et al; DRIVE-SHIFT Study Group. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81:463–472. doi:10.1097/QAI.0000000000002056
  • Saladini F, Giammarino F, Hosseini BA, et al. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. J Antimicrob Chemother. 2021;76:130–134. doi:10.1093/jac/dkaa401
  • Bangsberg DR, Ragland K, Monk A, et al. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24:2835–2840. doi:10.1097/QAD.0b013e328340a209
  • Cotte L, Ferry T, Pugliese P, et al. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - results from a large French multicenter cohort study. PLoS One. 2017;12:e0170661. doi:10.1371/journal.pone.0170661
  • Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-A-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–125.
  • Steegen K, Moorhouse M, Wensing AM, et al. Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa. J Int AIDS Soc. 2021;24:e25706. doi:10.1002/jia2.25706
  • Tsai HC, Chen IT, Wu KS, et al. High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014. Infect Drug Resist. 2017;10:343–352. doi:10.2147/IDR.S146584
  • Canducci F, Barda B, Ceresola E, et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect. 2011;17:928–934. doi:10.1111/j.1469-0691.2010.03375.x
  • Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204:1811–1815. doi:10.1093/infdis/jir636
  • Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27:111–121.
  • Stanford University HIV drug resistance database. Version 9.0. Available from: https://hivdb.stanford.edu. Accessed June 2, 2021.
  • Sterrantino G, Borghi V, Callegaro AP, et al. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019;53:515–519. doi:10.1016/j.ijantimicag.2019.02.007
  • Soulie C, Santoro MM, Storto A, et al. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. J Antimicrob Chemother. 2020;75:1026–1030. doi:10.1093/jac/dkz553
  • Miti S, Handema R, Mulenga L, et al. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia. PLoS One. 2020;15:e0236156. doi:10.1371/journal.pone.0236156
  • Guerrero-Beltrán C, Martínez-Sanz J, Álvarez M, et al. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. J Antimicrob Chemother. 2020;75:1294–1300. doi:10.1093/jac/dkaa009
  • Tsai HC, Chen IT, Tsai KW, et al. Prevalence of HIV-1 integrase strand transfer inhibitor resistance in treatment-naïve voluntary counselling and testing clients by population sequencing and illumina next-generation sequencing in Taiwan. Infect Drug Resist. 2020;13:4519–4529. doi:10.2147/IDR.S273704

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.